无码人妻21p,日本不卡VS一区二区,按摩按到少妇出水,又色又爽又黄的视频女女

搜索
篩選
全部清除
發(fā)表時間
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
產(chǎn)品類型
Luc陰性對照慢病毒
研究領域
腫瘤
神經(jīng)
代謝
內臟
mRNA疫苗
膀胱癌
細胞癌
肝臟
前列腺癌
細胞轉錄
乳腺癌
視網(wǎng)膜細胞癌
直腸癌
炎癥
阿茲海默癥
卵巢癌
甲狀腺癌
宮頸癌
急性髓系白血病
高血糖
糖尿病
冠狀病毒
胃癌
其他
結直腸癌
頭頸癌
腎炎
肝癌
肺癌
肺腺癌
鼻咽癌
胰腺癌
骨癌
減肥
哮喘
免疫
腎癌
當前位置：資源中心 > 客戶文獻
客戶文獻
共 328 內容
IF=11.6,Theranostics,同濟大學醫(yī)學院上海東方醫(yī)院,siRNA合成.
Endothelial S1pr2 regulates post-ischemic angiogenesis via AKT/eNOS signaling pathway
IF=12.9101,Molecular Therapy,上海交通大學醫(yī)學院附屬仁濟醫(yī)院,過表達質粒
Terbinafine prevents colorectal cancer growth by inducing dNTP starvation and reducing immune suppression
IF=19.5673,Emerging Microbes & Infections,四川大學華西醫(yī)院生物治療國家重點實驗室,假病毒.
An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological-and endosomal-pH to inhibit virus entry
IF=16.9885,Cell Reports Medicine,上?？萍即髮W生命科學與技術學院,Jurkat細胞.
Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity
IF=10.383,ACS Applied Materials & Interfaces,北京協(xié)和醫(yī)學院,假病毒.
Peptide Binder with High-Affinity for the SARS-CoV-2 Spike Receptor-Binding Domain
IF=11.092，Advanced Healthcare Materials,中國藥科大學，過表達質粒.
Metabolic Symbiosis-Blocking Nano-combination for Tumor Vascular Normalization Treatment
IF=10.787,Redox Biology ,江蘇中國藥科大學中藥學院,過表達質粒.
Ginsenoside Rb1 inhibits astrocyte activation and promotes transfer of astrocytic mitochondria to neurons against ischemic stroke
IF=12.153,Experimental and Molecular Medicine,上海交通大學醫(yī)學院附屬上?？傖t(yī)院,siRNA合成.
TGF-β promotes pericyte-myofibroblast transition in subretinal fibrosis through the Smad2/3 and Akt/mTOR pathways
IF=23.1777,Nature Cancer,上海交通大學醫(yī)學院仁濟醫(yī)院,過表達質粒.
Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer
IF=11.6,Theranostics. ,上海交通大學醫(yī)學院附屬仁濟醫(yī)院,質粒.
Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancer
首頁 18 19 20 21 22 末頁
共 33 頁
跳轉
當前位置：資源中心 > 客戶文獻
篩
選
客戶文獻
共 328 內容
IF=11.6,Theranostics,同濟大學醫(yī)學院上海東方醫(yī)院,siRNA合成.
Endothelial S1pr2 regulates post-ischemic angiogenesis via AKT/eNOS signaling pathway
IF=12.9101,Molecular Therapy,上海交通大學醫(yī)學院附屬仁濟醫(yī)院,過表達質粒
Terbinafine prevents colorectal cancer growth by inducing dNTP starvation and reducing immune suppression
IF=19.5673,Emerging Microbes & Infections,四川大學華西醫(yī)院生物治療國家重點實驗室,假病毒.
An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological-and endosomal-pH to inhibit virus entry
IF=16.9885,Cell Reports Medicine,上?？萍即髮W生命科學與技術學院,Jurkat細胞.
Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity
IF=10.383,ACS Applied Materials & Interfaces,北京協(xié)和醫(yī)學院,假病毒.
Peptide Binder with High-Affinity for the SARS-CoV-2 Spike Receptor-Binding Domain
IF=11.092，Advanced Healthcare Materials,中國藥科大學，過表達質粒.
Metabolic Symbiosis-Blocking Nano-combination for Tumor Vascular Normalization Treatment
IF=10.787,Redox Biology ,江蘇中國藥科大學中藥學院,過表達質粒.
Ginsenoside Rb1 inhibits astrocyte activation and promotes transfer of astrocytic mitochondria to neurons against ischemic stroke
IF=12.153,Experimental and Molecular Medicine,上海交通大學醫(yī)學院附屬上海總醫(yī)院,siRNA合成.
TGF-β promotes pericyte-myofibroblast transition in subretinal fibrosis through the Smad2/3 and Akt/mTOR pathways
IF=23.1777,Nature Cancer,上海交通大學醫(yī)學院仁濟醫(yī)院,過表達質粒.
Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer
IF=11.6,Theranostics. ,上海交通大學醫(yī)學院附屬仁濟醫(yī)院,質粒.
Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancer
MORE
篩選
全部清除
發(fā)表時間
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
產(chǎn)品類型
Luc陰性對照慢病毒
研究領域
腫瘤
神經(jīng)
代謝
內臟
mRNA疫苗
膀胱癌
細胞癌
肝臟
前列腺癌
細胞轉錄
乳腺癌
視網(wǎng)膜細胞癌
直腸癌
炎癥
阿茲海默癥
卵巢癌
甲狀腺癌
宮頸癌
急性髓系白血病
高血糖
糖尿病
冠狀病毒
胃癌
其他
結直腸癌
頭頸癌
腎炎
肝癌
肺癌
肺腺癌
鼻咽癌
胰腺癌
骨癌
減肥
哮喘
免疫
腎癌
重置
確定
Tel: 400-627-9288
留言咨詢
重置
提交
客服
微信
電話
留言
留言咨詢
重置
提交